Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000411920 | SCV000485407 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2015-12-11 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV000411920 | SCV000894386 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV000411920 | SCV001575161 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2023-11-20 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 8 of the PKHD1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PKHD1 are known to be pathogenic (PMID: 19940839). This variant is present in population databases (rs757521428, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PKHD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 370164). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Baylor Genetics | RCV003475940 | SCV004202220 | likely pathogenic | Polycystic kidney disease 4 | 2023-10-23 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV000411920 | SCV002083399 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2019-02-04 | no assertion criteria provided | clinical testing |